CDx - Research & Development Services
Routine clinical use of CDx testing has already detected thousands of precancers and cancers that would otherwise have been missed in time for effective endoscopic treatment. CDx Diagnostics is looking to apply the WATS3D platform to prevent cancers of the bile duct, stomach, and colon.
-
Most popular related searches
Services Overview
CDx Diagnostics is committed to helping make cancer a preventable disease through innovative technology – starting with WATS3D for esophageal cancer.
But we’re not stopping there…
Future Vision
CDx Diagnostics is expanding the application of our proprietary technology - developing tests in the digestive tract by adapting the approach of the WATS3D diagnostic platform to detect precancerous changes and prevent cancers of the bile duct, stomach, and colon - cancers with poor prognoses without improved diagnostics to reliably detect precancer before it can progress to cancer.
- ≤65% >5-Year Survival Rate (Stage I Stomach Cancer)
- ≤35% >5-Year Survival Rate (Stage II Stomach Cancer)
- ≤9% >5-Year Survival Rate (All Stages of Pancreatic Cancer Combined)
Ongoing R&D
CDx Diagnostics has a dedicated team of world-class imaging and artificial intelligence engineers and developers committed to pushing the edge of impossibility to create next-generation diagnostic and histocytology solutions.
Customer reviews
No reviews were found for CDx - Research & Development Services. Be the first to review!